Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value.

Int J Alzheimers Dis · 2010 · PMC3004402 · PMID 21197086

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

In a large multicentre trial only a nonsignificant trend to improvement in the circadian rhythm disturbance of AD is when treatment was done using melatonin [ 120 ].

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.